Today: 28 April 2026
Ondas Holdings (ONDS) stock drops after hours as investor day lifts 2026 revenue target
17 January 2026
2 mins read

Ondas Holdings (ONDS) stock drops after hours as investor day lifts 2026 revenue target

New York, January 16, 2026, 6:20 PM ET — Post-market update.

  • Shares of Ondas Holdings dipped after the bell, reacting to the latest Investor Day update
  • Company raised its 2026 revenue target and indicated a stronger preliminary revenue outlook for 2025
  • The next milestone to watch is March results, along with any updates from the subsequent Investor Day.

Ondas Holdings Inc., recently rebranded as Ondas Inc., saw its shares drop 5.3% in after-hours trading Friday, closing at $12.16. The stock swung sharply during the session, peaking at $14.20 before sliding back to $12.10. Roughly 168 million shares traded hands.

This move is crucial as the company wants investors to factor in a fresh growth trajectory ahead of its audited year-end results. With the stock behaving like a headline magnet recently, there’s barely any space for vague guidance.

Ondas laid down clearer revenue and cash targets during Friday’s Investor Day, sketching out its 2026 outlook. Now, traders face the question: are these goals conservative baselines, ambitious peaks, or simply shifting benchmarks?

Ondas boosted its 2026 revenue forecast to $170 million–$180 million, a 25% jump from the previous $140 million target, according to a recent filing. The company also reported its pro-forma cash balance topped $1.5 billion as of Dec. 31, following a roughly $1.0 billion offering. Alongside that, Ondas released preliminary 2025 numbers, projecting Q4 revenue between $27.0 million and $29.0 million, full-year revenue in the range of $47.6 million to $49.6 million, and an estimated year-end backlog of $65.3 million.

The company noted the figures are unaudited and preliminary, provided in an SEC filing but not formally “filed,” a legal nuance that limits some liabilities. It plans to release full results for the quarter and year ending Dec. 31 in March.

A separate filing revealed that Ondas officially shortened its corporate name from “Ondas Holdings Inc.” to “Ondas Inc.” as of Jan. 16. The company also revised its bylaws and incentive plans accordingly. Its Nasdaq ticker, ONDS, remains unchanged.

Ondas markets autonomous aerial and ground systems alongside private wireless networking equipment tailored for industrial use. Investor Day spotlighted its autonomous security platforms, especially counter-UAS—systems built to detect or interfere with drones.

Backlog represents the value of orders still awaiting recognition as revenue and can shrink if customers postpone, alter, or cancel projects. Pro-forma cash is an adjusted figure showing the balance sheet post-transaction—in this instance, following a sizable recent financing.

The risk is straightforward: preliminary numbers can shift, and revenue goals may fall short—especially when they depend on rolling acquisitions into the mix and turning backlog into timely shipments. Should the March report reveal thinner margins or sluggish orders compared to expectations, the stock could quickly adjust downwards.

U.S. markets were closed Monday in observance of Martin Luther King Jr. Day. Investors will have to wait until Tuesday for the next regular trading session to respond.

Traders will be looking for any follow-up from Investor Day — whether it’s slides, fresh backlog details, or announcements of new customer wins. Then attention will shift to the March reporting date, when the company’s audited 2025 results and 2026 outlook face real numbers instead of targets.

Stock Market Today

  • Novo Nordisk Gains FDA Fast Track for Coramitug, Bolsters Rare Disease Pipeline
    April 27, 2026, 9:55 PM EDT. Novo Nordisk (CPSE:NOVO B) secured U.S. FDA Fast Track designation for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy, marking a significant expansion beyond its core diabetes and obesity treatments. The pharma also reported positive Phase 3 results for etavopivat in sickle cell disease, further strengthening its rare disease portfolio. Despite a mixed share performance-up 15.3% in the past month but down 33.5% over a year-analysts see potential upside as shares trade 14% below targets and 65.7% under fair value estimates based on discounted cash flow (DCF). Investors should monitor ongoing trial progress and regulatory milestones amid existing financial risks, including debt and dividend concerns. The rare disease focus could diversify revenue streams and attract new investor interest.

Latest article

US Stock Market Today: S&P 500, Nasdaq Hit Records as After-Hours Trading Edges Higher

US Stock Market Today: S&P 500, Nasdaq Hit Records as After-Hours Trading Edges Higher

28 April 2026
The S&P 500 and Nasdaq closed at record highs Monday, while the Dow slipped 62.67 points to 49,168.04. After-hours, major U.S. indexes edged up less than 0.2%. Nvidia jumped 4% to a new high, topping $5 trillion in value, while Domino’s Pizza fell after forecasting weaker 2026 growth. Investors await Big Tech earnings and a Federal Reserve decision this week.
Netflix stock barely moves after hours as KeyBanc cuts target ahead of Warner deal-heavy earnings
Previous Story

Netflix stock barely moves after hours as KeyBanc cuts target ahead of Warner deal-heavy earnings

Western Digital (WDC) stock price: Analysts lift targets as SanDisk stake sale, earnings loom
Next Story

Western Digital (WDC) stock price: Analysts lift targets as SanDisk stake sale, earnings loom

Go toTop